1939P Potential role of longitudinal plasma next generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) experiencing hyperprogression (HPD) and early death (ED) during treatment with immune checkpoint inhibitors (ICIs)

L Bonanno,G Nardo,G Pasello,V Guarneri,I Attili,A Pavan,E Zulato,P.F Conte,D.B Paola,A Boscolo Bragadin,S Indraccolo

doi:10.1016/j.annonc.2020.08.1332

1939P Potential role of longitudinal plasma next generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) experiencing hyperprogression (HPD) and early death (ED) during treatment with immune checkpoint inhibitors (ICIs)

L Bonanno, G Nardo + Show 9 more

Open Access

https://doi.org/10.1016/j.annonc.2020.08.1332

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2020
Citations: 2	License type: publisher-specific-oa

Affiliation: Istituto Oncologico Veneto, Istituti di Ricovero e Cura a Carattere Scientifico

#Immune Checkpoint Inhibitors In Clinical Practice #Introduction Of Immune Checkpoint Inhibitors + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The introduction of ICIs in clinical practice has revolutionized aNSCLC treatment but a proportion of pts does not benefit from ICIs and could even derive detrimental effects. No predictive markers are currently available for their early detection. Aim of the study was to characterize pts experiencing HPD and ED with plasma NGS to analyze their modification at an early time-point during treatment.

Full Text